Disease | Cargo | Target/Pathway | Donor Cell | Recipient Cell | Main Function | Reference |
---|---|---|---|---|---|---|
Ischemic Stroke (IS) | MiR-98 | Platelet-activating factor receptor | Neuron | Microglia | Attenuate neuronal death after IS | [39] |
Transmembrane tumor necrosis factor | - | Regenerative microglia | Oligodendrocyte precursor cell (OPC) | Promote the OPC maturation and ameliorate neurological function after IS | [40] | |
MiR-23a-5p | OLIG3-oligodendrocyte transcription factor 3 | M2 microglia | OPC | Promote white matter repair and functional recovery after IS | [41] | |
MiR-124 | Signal transducer and activator of transcription 3 | M2 microglial | Astrocyte | Attenuate glial scar formation and promote recovery after IS | [42] | |
- | - | Astrocyte | Neuron | Promote axonal growth and neuronal survival after IS | [44] | |
- | - | Activated astrocyte | Neuron | Regulate axonal growth after ischemia | [45] | |
MiR-25-3p | p53 pathway | Mesenchymal stem cell (MSC) | Neuron | Inhibit autophagy and have neuroprotective effects | [46] | |
MiR-125b-5p | Toll-like receptor 4 (TLR4) and nuclear transcription factor-kappaB (NF-κB) signaling | MSC | Astrocyte | Attenuate BBB integrity disruption induced by tPA and alleviate hemorrhage | [47] | |
TGF-β, Smad2, and Smad4 | TGF-β/Smad signaling pathway | Embryonic stem cell (ESC) | Regulatory T cell | Alleviate neuroinflammation and promote long-term neurological recovery after IS | [48] | |
Intracerebral Hemorrhage (ICH) | - | - | Multipotent mesenchymal stromal cell | - | Promote neurogenesis and angiogenesis and improve functional recovery after ICH | [50] |
MiR-23b | Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and PTEN/Nrf2 pathway | Bone marrow mesenchymal stem cell (BMSC) | Microglia/macrophage | Exhibit antioxidant effects and promote neurologic function recovery after ICH | [51] | |
MiR-19b-3p | Iron regulatory protein 2 | Adipose-derived stem cell (ADSC) | Neuron | Alleviate neuronal ferroptosis and improve neurological function after ICH | [52] | |
Signal regulatory protein α (SIRPα)- variants | CD47 | MSC | Red blood cell | Accelerate hematoma clearance and ameliorate white matter injury after ICH | [53] | |
MiR-383-3p | Activating transcription factor 4 | Activated microglia | Neuron | Promote neuron necroptosis after ICH | [54] | |
Vascular Dementia (VD) | MiR-154-5p | Protein kinase AMP-activated catalytic subunit alpha 2 (PRKAA2) | - | Endothelial progenitor cell (EPC) | Inhibit EPC functions and inhibit angiogenesis | [58] |
MiR-132-3p | Ribosomal arginine synthetase 1 and Ras/Akt/GSK-3β pathway | MSC | Neuron | Improve synaptic dysfunction and cognitive decline in VD | [59] | |
MiR-17-5p, miR-18a-5p, miR-21-5p, miR-29a-3p, and let-7a-5p | Rapamycin complex 1 | ESC | Hippocampal neural stem cell (HNSC) | Ameliorate senescence-related neurogenesis dysfunction and cognitive impairment in VD | [61] | |
MIAT | MiR-34b-5p/CALB1 axis | HNSC | Hippocampal neuronal cell | Improve cognitive disorders in VD | [62] | |
Cerebral Small Vascular Disease (CSVD) | - | - | MSC | Microglia | Attenuate inflammation in CSVD | [64] |
Hypertension | MiR-320d/423-5p | - | Endothelial cell (EC) | Subendothelial smooth muscle cell (SMC) | Cause arterial remodeling in hypertension | [70] |
MiR-483-3p | Angiotensin-converting enzyme I (ACE I), CTGF, TGF-β | EC | SMC | Inhibit endothelial dysfunction and exert protective effects on EC function during the onset of hypertension | [71] | |
ACE | - | Adventitial fibroblast | Vascular smooth muscle cell (VSMC) | Cause VSMC proliferation and vascular remodeling and hypertension | [72] | |
MiR-155-5p | ACE | Adventitial fibroblast | VSMC | Attenuate VSMC proliferation and vascular remodeling in hypertension | [73] | |
MiR-135a-5p | Fibronectin type III domain containing 5 (FNDC5) | Adventitial fibroblast | VSMC | Promote VSMC proliferation in hypertension | [74] | |
Atherosclerosis | MiR-92a | Krüppel-like factor 4 (KLF4) | EC | Macrophage | Cause atherosclerotic lesion formation in atherosclerosis | [78] |
- | - | Monocyte/platelet | EC | Trigger differential activation of human atherosclerotic plaque in atherosclerosis | [79] | |
MiR-221 | N-acetyltransferase-1 | BMSC | SMC | Inhibit atherosclerotic plaque formation against atherosclerosis | [80] | |
MiR-146a | Src signal pathway | MSC | Senescent EC | Mitigate EC senescence and stimulate angiogenesis during atherosclerosis | [81] | |
MiR-27b-3p | Peroxisome proliferator-activated receptor α | Visceral adipocyte | EC | Promote endothelial inflammation and facilitate atherogenesis in atherosclerosis | [82] | |
MiR-155 | BCL2, MCL1, TIMP3, BCL6 | Nicotine-stimulated monocyte | EC | Promote plaque formation and trigger vascular endothelial injury in atherosclerosis | [83] | |
MiR-21-3p | PTEN | Nicotine-stimulated macrophage | VSMC | Increase VSMC migration and proliferation and accelerate atherosclerosis development | [84] | |
Acute Mycardial Infarction (AMI) | - | C-X-C chemokine receptor type 4 | Infarcted cardiomyocyte | Bone marrow monocyte | Promote cardiac repair after AMI | [86] |
CircUbe3a | MiR-138-5p/RhoC axis | M2 macrophage | Cardiac fibroblast | Exacerbate myocardial fibrosis after AMI | [87] | |
MiR-155 | RAC1, RAK2, Sirt1, Enos, and AMPKa2 | M1 macrophages | EC | Inhibit angiogenesis and aggravate heart injury after AMI | [88] | |
MiR-125b-5p | - | MSC | Cardiomyocyte | Inhibit autophagic after AMI | [90] | |
MiR-486-5p | Matrix metalloproteinase 19 | Hypoxia-preconditioned MSC | Cardiac fibroblast | Promote angiogenesis after AMI | [91] | |
- | Foxo3 | - | Regulatory T cell | Inhibit cardiac inflammation and promote cardiac repair after AMI | [92] | |
Myocardial Ischemia–Reperfusion Injury (MIRI) | Linc-ROR | MiR-145-5p | Cardiomyocyte | Cardiac microvascular endothelial cell (CMEC) | Increase the survival of CMECs and CMs and attenuate MIRI injury | [95] |
Cardioprotective proteins | - | EC | Cardiomyocyte | Attenuate cardiac injury after MIRI | [96] | |
MiR-24-3p | CCR2 | KLF2-overexpressing EC | Monocyte | Inhibit monocyte recruitment and attenuate MIRI | [97] | |
MiR-130b-3p | AMPKα1/α2, Birc6, and Ucp3 | Diabetic adipocytes | Cardiomyocyte | Induce proapoptotic/cardiac harmful effects and exacerbate MIRI | [98] | |
Damaged mitochondria | - | Energetically stressed adipocyte | Cardiomyocyte | Protect cardiomyocytes against oxidative stress after MIRI | [99] | |
MiR-210 | Ephrin A, protein tyrosine phosphatase 1B, and death-associated protein kinase 1 | ADSC | EC and cardiomyocyte | Promote angiogenesis and inhibit apoptosis after MIRI | [100] | |
Heart Failure (HF) | MiR-378 | Mitogen-activated protein kinase kinase 6 | Cardiomyocytes under the overloaded condition | Cardiac fibroblasts | Inhibit excessive fibrosis in HF | [102] |
MiR-21-5p | PTEN/Akt signaling pathway | Cardiac stromal cell | Cardiomyocyte | Enhance angiogenesis and cardiomyocyte survival in HF | [103] | |
- | MiR-200b | Human trophoblast stem cell | - | Have antiapoptotic and anti-inflammatory effects and attenuate doxorubicin-induced cardiac injury in HF | [105] | |
MiR-100-5p | NADPH oxidase 4 | MSC | Cardiomyocyte | Suppress oxidative stress and play cardioprotective roles in HF | [101] | |
- | - | ESC | Macrophage | Attenuate pyroptosis and cardiac remodeling induced by Doxorubicin | [106] | |
Mitochondrial transcription factor A and mtDNA | - | MSC | - | Mitigate mitochondrial injury and inflammation in AKI | [161] | |
VEGF-A | Vascular endothelial growth factor receptor (VEGFR) | Tubular epithelial cell (TEC) | - | Promote angiogenesis after AKI | [162] | |
Diabetic Nephropathy (DN) | Chemokine ligand 7 | Rapamycin complex 1 pathway | platelet | Glomerular endothelial cell | Exacerbate glomerular endothelial damage and promote the progression of DN | [107] |
MiR-19b-3p | Suppressor of cytokine signaling 1 | TEC | Macrophage | Drive the development of tubulointerstitial inflammation in DN | [108] | |
Leucine-rich α-2-glycoprotein 1 | TGF-β R1 | TEC | Macrophage | Promote inflammation and induce macrophages to secret EVs in DN | [109] | |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) | Death receptor 5 (DR5) | Macrophage | TEC | Induce TEC apoptosis and promote DN | [109] | |
MiR-199a-5p | Klotho | TEC | Macrophage | Stimulate M1 polarization and accelerate DN | [110] | |
MiR-93-5p | TLR4 | Macrophage | Podocyte | Alleviate podocyte apoptosis and inhibit DN development | [111] | |
- | mTOR | MSC | - | Suppress autophagy and alleviate DN | [112] | |
MiR-486 | Smad1/mTOR signaling pathway | ADSC | Podocyte | Promote autophagy flux, inhibit apoptosis, and ameliorate DN | [113] | |
14–3-3 ζ | Yes-associated protein | MSC | Podocyte | Promote autophagy and prevent DN | [114] | |
Diabetic Retinopathy (DR) | MiR-9-3p | Sphingosine-1-phosphate receptor 1 | Retinal Muller cell | Retinal endothelial cell (REC) | Promote abnormal angiogenesis and aggravate DR | [115] |
CircEhmt1 | NFIA/NLRP3 pathway | Pericyte | Retinal microvascular endothelial cell (RMEC) | Improve microvascular dysfunction and ameliorate DR | [116] | |
MiR-30c-5p | Phospholipase C gamma 1 | MSC | REC | Inhibit inflammation in DR | [117] | |
Neuronal precursor cell-expressed developmentally downregulated 4 | PTEN | MSC | Retinal pigment epithelium cell | Inhibit apoptosis and oxidative damage and prevent DR development | [118] | |
MiR-192 | Integrin alpha 1 | MSC | - | Alleviate inflammation and angiogenesis in DR | [119] | |
MiR-18b | Mitogen-activated protein kinase 1 | MSC | RMEC | Inhibit inflammation and apoptotic in DR | [120] | |
Diabetic Cardiomyopathy (DCM) | MiR-326-3p | Rictor | Senescent adipocyte | Cardiomyocyte | Cause mitochondrial dysfunction and cardiac diastolic dysfunction in DCM | [123] |
Mst1 | Daxx | CMEC | Cardiomyocyte | Inhibit autophagy, promote apoptosis, and alleviate DCM | [124] | |
MiR-499, miR-133a, and miR-133b | - | Cardiomyocyte | Cardiomyocyte | Inhibit autophagy and oxidative stress and attenuate DCM | [125] | |
- | - | Cardiac parasympathetic neuron | Cardiac fibroblast | Inhibit apoptosis and DCM progression | [126] | |
TGF-β1 mRNA | - | CMEC | Cardiac fibroblast | Promote myocardial fibrosis in DCM | [127] | |
Diabetic Foot Ulcers (DFU) | Nuclear factor-erythroid factor 2 (Nrf2) | - | ADSC | EPC | Promote wound healing in DFU | [128] |
Linc00511 | Progestin and adipoQ receptor 3 | ADSC | EPC | Promote angiogenesis and attenuate DFU | [129] | |
Mmu_circ_0001052 | MiR-106a-5p | ADSC | EC | Promote angiogenesis and wound healing and attenuate DFU | [130] | |
LncRNA H19 | MiR-152-3p | MSC | Fibroblast | Inhibit apoptosis and inflammation and ameliorate wound ulcers in DFU | [131] | |
MiR-106-5p | Extracellular signal-regulated kinase 1/2 | EC | Fibroblast | Activate autophagy and inhibit wound healing in DFU | [132] | |
LINC01435 | YY1 | Epidermal cell | EC | Delay the wound healing process of DFU | [133] | |
Hemangioma | MiR-187-3p | Notch signaling | MSC | Hemangioma stem cell (HemSC) | Suppress HemSC proliferation in hemangioma | [134] |
MiR-27a-3p | Dickkopf-related protein 2 | Tumor-associated macrophage | HemSC | Suppress propranolol sensitivity and decrease apoptosis in hemangioma | [135] | |
MiR-196b-5p | Cyclin-dependent kinase inhibitor 1B | HemSC | Hemangioma endothelial cell (HemEC) | Enhance proliferation and angiogenesis and attenuate apoptosis of HemECs in hemangioma | [136] | |
MiR-210 | Homeobox A9 | Hypoxia-induced EC | HemEC | Enhance the proliferation and migration of HemECs and inhibit apoptosis of HemECs in hemangioma | [137] | |
Hematological Malignancies | Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) messenger RNA | VEGFR | Acute myeloid leukemia (AML) cell | EC | Stimulate vascular remodeling and chemoresistance in AML | [140] |
- | - | AML cell | EC | Promote angiogenesis in AML | [141] | |
- | - | Chronic myeloid leukemia (CML) cell | EC | Promote angiogenesis in CML | [142] | |
Chloride intracellular channel 1 | ITGβ1 | Chronic lymphocytic leukemia (CLL) cell | EC | Promote angiogenesis in CLL | [143] | |
- | - | Diffuse large B cell lymphoma (DLBCL) cell | EC | Promote angiogenesis in DLBCL | [144] | |
VEGF | VEGF/Akt signaling pathway | Lymphoma cells treated with curcumin and omacetaxine | EC | Inhibit angiogenesis in lymphoma | [145] | |
Other Solid Tumors | miR-25-3p | KLF2 and KLF4 | CRC cell | EC | Promote angiogenesis and metastasis in CRC | [147] |
Glutamine-fructose-6-phosphate aminotransferase 1 | - | Bladder cancer cell | EC | Realize metabolic reprogramming and promote angiogenesis in bladder cancer | [148] | |
Lysyl oxidase-like 4 (LOXL4) | The FAK/Src pathway | Hepatocellular carcinoma (HCC) | EC | Promote angiogenesis, enhance invasion, and exacerbate HCC metastasis | [149] | |
MiR-9 | Collagen type XVIII alpha 1 chain, thrombospondin 2, patched 1, and prolyl hydroxylase domain 3 | Glioma cell | EC | Promote angiogenesis in glioma | [150] | |
MiR-9 | MDK | Nasopharyngeal carcinoma cell | EC | Inhibit angiogenesis in nasopharyngeal carcinoma | [151] | |
MiR-522 | Arachidonate lipoxygenase 15 | Cancer-associated fibroblast (CAF) | Gastric cancer cell | Inhibit ferroptosis and induce chemical resistance | [152] | |
EGFR | PI3K/AKT and MAPK pathways | Wild EGFR non-small cell lung cancer (NSCLC) cell | Mutated EGFR NSCLC cell | Promote the resistance to osimertinib | [154] | |
Acute Lung Injury (ALI) | MiR-30d-5p | Suppressor of cytokine signaling 1 and Sirt1 | Polymorphonuclear neutrophil | Macrophage | Induce M1 macrophage polarization and pyroptosis and aggravate ALI | [155] |
mtDNA | - | MSC | Macrophage | Reduce inflammation and improve ALI | [156] | |
MiR-125b-5p | Keap1 | ADSC | Pulmonary microvascular endothelial cell (PMVEC) | Alleviate inflammation and improve ALI | [157] | |
MiR-126-3p and MiR-126-5p | Phosphoinositide-3-kinase regulatory subunit 2 | EPC | EC | Inhibit inflammation and microvascular dysfunction and alleviate ALI | ||
Acute Kidney Injury (AKI) | MiR-200a-3p | Keap1 | MSC | TEC | Enhance mitochondrial function and improve renal function during AKI | [160] |
Mitochondrial transcription factor A and mtDNA | - | MSC | - | Mitigate mitochondrial injury and inflammation in AKI | [161] | |
VEGFA | VEGFR | TEC | - | Promote angiogenesis after AKI | [162] |